Nerlynx (Neratinib)

Neratinib, the active ingredient in Nerlynx, is a tyrosine kinase inhibitor presented as a 240 mg capsule for oral use. It treats HER2‑positive breast cancer in patients who have completed trastuzumab‑based therapy and in those with metastatic disease.

GNH USA supplies Nerlynx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nerlynx is used in HER2‑positive breast cancer management, targeting both early‑stage and metastatic disease.

- Extended adjuvant treatment of HER2‑positive breast cancer: reduces risk of recurrence after trastuzumab‑based therapy. - HER2‑positive metastatic breast cancer: helps control tumor progression in advanced disease.

Nerlynx may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent, may be severe. - Nausea and vomiting: gastrointestinal upset. - Fatigue: reduced energy levels. - Rash or skin irritation: mild to moderate.

Serious or Rare Side Effects: - Severe or persistent diarrhea leading to dehydration. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Interstitial lung disease or pneumonitis: respiratory symptoms.

When prescribing Nerlynx, clinicians should observe several safety precautions to minimize risks. - Monitor for diarrhea: initiate antidiarrheal prophylaxis and assess hydration status. - Assess liver function: perform baseline and periodic transaminase testing. - Evaluate cardiac status: obtain baseline ejection fraction and monitor for dysfunction. - Avoid use in pregnancy: teratogenic risk; ensure effective contraception. - Review concomitant medications: check for CYP3A4 inhibitors or inducers. - Store at ambient temperature: keep below 25 °C, protect from moisture, retain original packaging.

Neratinib interacts with several drug classes; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase neratinib exposure and toxicity. - Antacids containing aluminum or magnesium: reduce oral absorption of neratinib. - Co‑administration with other HER‑targeted TKIs: may amplify adverse effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): decrease neratinib effectiveness. - Antidiarrheal agents (e.g., loperamide): may mask severity of neratinib‑related diarrhea. - Warfarin: may require more frequent INR monitoring.